Exagen Reports Record Full-Year Revenue and Positive 2026 Guidance
Summary
Exagen Inc. announced record full-year 2025 revenue of $66.6 million, a 20% increase, and issued 2026 revenue guidance of $70-$73 million, alongside a strengthened cash position.
Key Events
-
Record Full-Year Revenue
Achieved record total revenue of $66.6 million for 2025, marking a 20% increase from the previous year.
-
Positive 2026 Guidance
Provided full-year 2026 revenue guidance in the range of $70 million to $73 million, indicating expected continued growth.
-
Strengthened Balance Sheet
Ended 2025 with $32.4 million in cash, cash equivalents, and restricted cash, bolstered by a $20 million public offering and a $25 million credit facility.
-
Operational Growth
Grew AVISE CTD test volume by over 11% and expanded its average selling price (ASP) by 7% in 2025.
Analysis
Exagen Inc. reported strong financial results for the full year 2025, achieving record total revenue of $66.6 million, a 20% increase year-over-year. The company also provided optimistic revenue guidance for 2026, projecting $70 million to $73 million. While the company continues to operate at a net loss, it significantly bolstered its cash position to $32.4 million through a $20 million public offering and a $25 million credit facility, which management states positions them for cash flow positivity. This update provides a comprehensive view of the company's performance and future outlook, indicating continued growth and improved financial stability.
At the time of this filing, XGN was trading at $3.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $76.6M. The 52-week trading range was $2.77 to $12.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.